GeoVax reports 2025 net loss $21.5M; Phase 3 trial for mpox vaccine planned H2 2026

GeoVax Labs, Inc.

Net loss $21.5M ($22.40/share) vs $25.0M ($120.46/share) in 2024; revenue $2.5M from BARDA contract.
Cash $3.1M at Dec 31, 2025; R&D expenses $18.1M (down from $23.7M); BARDA contract terminated Apr 2025.
GEO-MVA Phase 3 trial to start H2 2026; EMA supports streamlined development without Phase 1/2.
GEO-CM04S1 COVID vaccine Phase 2 data in 2026; Gedeptin oncology Phase 2 planned for 2027.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

GeoVax Labs, Inc. reported the year ended December 31, 2025 results: revenue $2.5 million, net income $21.5 million, EPS $22.40 per share.

Period: the year ended December 31, 2025
Revenue: $2.5 million
Net income: $21.5 million
EPS: $22.40 per share
Result: reported results

Exact text from the filing

Net loss for the year ended December 31, 2025, was $21.5 million, or $22.40 per share, as compared to $25.0 million, or $120.46 per share, for the year ended December 31, 2024. Revenue : For the year ended December 31, 2025, the Company reported $2.5 million of government contract revenues associated with the BARDA/RRPV Project NextGen award, compared to $4.0 million during 2024.

View on SEC.gov

1347 earnings releases filed in the last 30 days. Browse all earnings releases →

GeoVax Labs, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-012435

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.